

"Express Mail" Label No.: EV583918239US

Date of Deposit: May 10, 2005

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Mail Stop Fee Amendment, P. O. Box 1450, Alexandria, VA 22313-1450.

Jane Massey Licata
Typed Name: Jane Massey Licata, Reg. No. 32,257

Mail Stop Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).



- In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.
- In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
 - Certification in Accordance with §1.97(e) is attached hereto; or
 - Authorization to charge Deposit Account No. 50-1619 the fee of \$180.00 as set forth in §1.17(p) is provided.
- In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).
- Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.



() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.


Respectfully submitted,

Jane Massey Licata
Jane Massey Licata
Registration No. 32,257

Date: May 10, 2005

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515



Sheet 01 of 01

Form PTO-1449 Modified		Docket No. P-633 (TI-0020)	Serial No. 09/873,645
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Taylor and Yu	
U.S. Department of Commerce		Filing Date June 4, 2001	Group 1631

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	Escary et al., "Screening strategy for mutation detection using denaturing high-performance liquid chromatography (DHPLC)", Int. Biotech Lab. 1999 19
CB	Kuklin et al., "Detection of Single-Nucleotide Polymorphisms with the WAVE™ DNA Fragment Analysis System", Genetic Testing 1997/1998 1(3):201-206
CC	Liu et al., "Denaturing HPLC-Identified Novel FBN1 Mutations, Polymorphisms, and Sequence Variants in Marfan Syndrome and Related Connective Tissue Disorders", Genetic Testing 1997/1998 1(4):237-242
CD	Yokomizo et al., "PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers", Oncogene 1998 17:475-479

EXAMINER	DATE CONSIDERED
----------	-----------------